While dihexa at 1 nM and 10 pM alone does not activate c-Met, it markedly augments the capacity of HGF at 1.25 and 2.5 ng/mL to activate c-Met [1]

3.2 Study data 3.2.1 Studies with a control group One controlled study comparing polysomnography (PSG) data of children with GHD with age-matched controls found that children with GHD had significantly lower total sleep time, sleep efficiency, movement time, and time spent in rapid eye movement (REM) sleep and stage 2 non-REM sleep, plus a general decrease in electroencephalogram (EEG) arousability ( In another controlled study, a group of seven children with GHD underwent PSG before and after 12 weeks of GH therapy ( The third controlled study included five children with GHD and 10 healthy controls ( 3.2.2 Studies without a control group In a study evaluating GH secretion during sleep in children with short stature, peaks of GH secretion were found to occur primarily during slow-wave and deep sleep ( There were several inconsistencies in the findings of the identified studies

Body Composition and Metabolic Parameters Research on component peptides revealed favorable effects on body composition and metabolic markers[10]: Significant reductions in waist circumference (10-15 cm reductions observed) Preferential visceral fat loss documented through imaging studies Preserved lean body mass relative to total weight loss in most studies Improved body composition ratios with fat mass reductions exceeding total weight loss percentages Type 2 Diabetes Research Glycemic Control Studies Investigations in type 2 diabetes models demonstrated robust glucose-lowering effects[11]: HbA1c reductions of 2.0-2.4% observed with GLP3 in phase 2 diabetes trials Fasting plasma glucose reductions of 40-60 mg/dL documented across dose ranges Improved continuous glucose monitoring parameters including time in range and glucose variability CagriSema combination achieved superior glycemic control compared to individual components Studies showed that 72% of participants with prediabetes reverted to normoglycemia with GLP3 treatment, suggesting potential diabetes prevention applications[12]

Kyrion, G., Boakye, K
Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, et al